Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | BMI1 | P35226 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1708107 | 0.92 | TSHR (0.46) | ALDH1A1POLBRAB9ATSHRCFTR | |
| SCHEMBL3797322 | 0.88 | ALDH1A1 (0.46) | ALDH1A1POLBTP53MYCMRGPRX4 | |
| SCHEMBL1708045 | 0.86 | ALDH1A1 (0.51) | ALDH1A1POLBRAB9ATSHRTP53 | |
| SCHEMBL1708108 | 0.85 | POLB (0.53) | ALDH1A1POLBRAB9ATSHRTP53 | |
| SCHEMBL1708100 | 0.84 | RAB9A (0.51) | ALDH1A1POLBRAB9ATSHRTP53 | |
| SCHEMBL3792099 | 0.79 | HSD17B10 (0.44) | ALDH1A1POLBTP53DHODHSORT1 | |
| SCHEMBL1708275 | 0.78 | BMI1 (0.37) | ALDH1A1TSHRDHODHBMI1PDE2A | |
| SCHEMBL1707974 | 0.77 | MAPK1 (0.47) | ALDH1A1POLBRAB9ATSHRTP53 | |
| SCHEMBL1708054 | 0.74 | ALDH1A1 (0.48) | ALDH1A1POLBRAB9ATSHRMYC | |
| SCHEMBL1707983 | 0.73 | CFTR (0.41) | ALDH1A1POLBRAB9ACFTRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| EP-2440541-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143733-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | GPR119, INSR, GLP1R | ALDH1A1 3930/4885POLB 4829/4885RAB9A 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.